Skip to content

No results found

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

RARE Ultragenyx Pharmaceutical Inc.
$19.23 -3.25% -0.65
Notify me if price changes either direction
Interactive Brokers Logotype

Buy RARE stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 1.9B
Enterprise value 2.5B
Trailing PE -3.3156089062961
Forward PE 247.18825
PEG Ratio 0.46086963797515
Enterprise to EBITDA -4.986
Enterprise to revenue 3.705
Price to book MRQ -26.452972498332
Price to sales TTM 2.8716135

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2025-12-31
Revenue (TTM) 673.0M
EBITDA -500000000
Diluted EPS TTM -5.83
Total Cash (MRQ) 680.0M
Current ratio (MRQ) 2.477
Operating Cash Flow (TTM) -466000000

RARE trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent RARE News

Home

No results found

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.